- Immix Biopharma's (IMMX, Financial) NXC-201 trial data slated for oral presentation at ASCO 2025.
- First U.S. trial of CAR-T therapy for relapsed/refractory AL Amyloidosis.
- Presentation scheduled for June 3, 2025, by Dr. Heather Landau in Chicago.
Immix Biopharma, Inc. (IMMX), a clinical-stage biopharmaceutical company, has announced that interim data from its Phase 1/2 NXC-201 NEXICART-2 trial has been selected for oral presentation at the American Society of Clinical Oncology Annual Meeting (ASCO 2025). This achievement highlights the potential significance of the trial data for treating relapsed/refractory AL Amyloidosis.
The presentation, titled "Safety and efficacy data from NEXICART-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201," will be delivered by Dr. Heather Landau, Director of the Amyloidosis Program at Memorial Sloan-Kettering Cancer Center. The session is scheduled for Tuesday, June 3, 2025, from 9:45 am to 12:45 pm CDT in Chicago, focusing on Hematologic Malignancies—Plasma Cell Dyscrasia (Abstract #7508).
NXC-201 is a sterically-optimized BCMA-targeted CAR-T cell therapy. It has shown promising results, with a complete response rate in early studies, and holds both Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation from the US FDA. The ongoing NEXICART-2 trial excludes patients with pre-existing heart failure and targets safety and efficacy as primary endpoints across its phases.
AL Amyloidosis is a condition characterized by misfolded amyloid proteins that cause organ damage, affecting the heart, kidney, and liver. The trial's selection for an oral presentation at ASCO suggests that the findings could have significant implications for treatment, as the need for effective therapies grows with the disease's increasing prevalence.
